126 related articles for article (PubMed ID: 23183388)
1. A 4-drug combination (Stribild) for HIV.
Med Lett Drugs Ther; 2012 Nov; 54(1404):95-6. PubMed ID: 23183388
[No Abstract] [Full Text] [Related]
2. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
Manzardo C; Gatell JM
AIDS Rev; 2014; 16(1):35-42. PubMed ID: 24584107
[TBL] [Abstract][Full Text] [Related]
3. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
Perry CM
Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
[TBL] [Abstract][Full Text] [Related]
4. Switching STRATEGIES in HIV treatment.
Schrijvers R; Debyser Z
Lancet Infect Dis; 2014 Jul; 14(7):537-40. PubMed ID: 24908549
[No Abstract] [Full Text] [Related]
5. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
[TBL] [Abstract][Full Text] [Related]
6. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
7. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
[TBL] [Abstract][Full Text] [Related]
8. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
Pozniak A; Markowitz M; Mills A; Stellbrink HJ; Antela A; Domingo P; Girard PM; Henry K; Nguyen T; Piontkowsky D; Garner W; White K; Guyer B
Lancet Infect Dis; 2014 Jul; 14(7):590-9. PubMed ID: 24908550
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
Raffe S; Fisher M
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):427-35. PubMed ID: 25553805
[TBL] [Abstract][Full Text] [Related]
10. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
11. Novel HIV-1 treatment Stribild™ gains regulatory approval.
Breeze S
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):613. PubMed ID: 23234321
[No Abstract] [Full Text] [Related]
12. Elvitegravir/cobicistat, mirabegron, and linaclotide.
Hussar DA; Martinez LN
J Am Pharm Assoc (2003); 2012; 52(6):860-2. PubMed ID: 23229974
[No Abstract] [Full Text] [Related]
13. Boosting HIV treatment options: good news, new challenges.
Cahn P; Sued O
J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
[No Abstract] [Full Text] [Related]
14. Improved adherence expected with new HIV combo treatment.
Morrow T
Manag Care; 2012 Nov; 21(11):53-4. PubMed ID: 23236718
[No Abstract] [Full Text] [Related]
15. Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Di Biagio A; Prinapori R; Taramasso L; Gustinetti G; Sticchi L; Bruzzone B; Viscoli C
Recent Pat Antiinfect Drug Discov; 2014; 9(1):41-51. PubMed ID: 25030944
[TBL] [Abstract][Full Text] [Related]
16. Drug updates and approvals: 2012 in review.
Belavic JM
Nurse Pract; 2013 Feb; 38(2):24-42; quiz 42-3. PubMed ID: 23295643
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
18. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Post FA; Winston J; Andrade-Villanueva JF; Fisher M; Liu Y; Beraud C; Abram ME; Graham H; Rhee MS; Cheng AK; Szwarcberg J;
J Acquir Immune Defic Syndr; 2015 Mar; 68(3):310-3. PubMed ID: 25469527
[TBL] [Abstract][Full Text] [Related]
19. FDA treads carefully with PrEP.
Holmes D
Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
[No Abstract] [Full Text] [Related]
20. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
